10
Jul
2023
Tag: Big Pharma / Specialty Pharma
29
May
2023
Bionest
GLP-1 Agonists: The Next Pharma El Dorado? – Part 2
Will GLP-1 agents ultimately find success in NASH in addition to diabetes and obesity? We explore applications in liver disease in part two of our series.
15
May
2023
Bionest
GLP-1 Agonists: The Next Pharma El Dorado? – Part 1
Will GLP-1RAs ultimately succeed in the marketplace for obesity treatments, where other weight loss drugs have failed? In the first of a two-part blog series, we explore their use as a treatment of Type 2 diabetes & obesity.
1
May
2023
Bionest
Reactions to the Inflation Reduction Act and Drug Pricing
What impact will the Inflation Reduction Act have on pharmaceutical businesses, innovation and patients?
20
Mar
2023
Bionest
FDA Finalizes Guidance on Multiple Endpoints in Clinical Trials
Assessing multiple endpoints in clinical trial results can prove challenging, prompting the FDA to provide new guidance for drug sponsors.
13
Mar
2023
Bionest
Alzheimer’s Disease Update Part 2: The Importance of Amyloid and Its Clearance in AD
Could cellular waste management be key in treating Alzheimer's Disease? We explore this emerging field of research and potential for new AD drugs.
21
Feb
2023
Bionest
Alzheimer’s Disease Update Part 1: Lecanemab Provides New Support for the Amyloid Hypothesis
What will the recent accelerated approval of anti-amyloid lecanemab mean for Alzheimers patients, and will it overcome stringent CMS reimbursement policies?
19
Dec
2022
Bionest
COVID Vaccines Transition from Government Supply to Private Marketplace
What will be the impact of moving COVID vaccines to the private marketplace? We examine both the challenges and new opportunities for the companies.
5
Dec
2022
Bionest
Medicare Drug Price Negotiations: Potential Impacts
What impact will the Inflation Reduction Act have on pharma & biotech companies and what should they consider in their pipeline development plans?
21
Nov
2022